Saturday, September 5, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&AAbbVie Files Material Event: Botox/Juvéderm Pricing ShifttodayDevices & TechDermatosurgical Device Market Set for $10.02B by 20302 days agoComplianceMed Spa Owner Sentenced to Prison for Counterfeit BotoxtodayInjectablesBotox Market to Reach $32.48B by 2035 at 9.15% CAGR2 days agoMarketOzempic Face Spawns New Beauty Market—Here's the PlaytodayDevices & TechRF Device Market Projected to Hit $2.15B by 20302 days agoRegulatoryMedicare to Negotiate Botox Pricing—What Practices Need to KnowtodayInjectablesSouth Korea Targets 'Ozempic Face' With Fat-Transfer Protocol2 days agoBusiness & M&AAllergan Aesthetics Revamps Allē ProgramyesterdayDevices & TechBTL Launches EXOLASE ONE: First Fused Erbium LaseryesterdayRegulatoryMedytox Wins Colombia Approval for Attier HAyesterdayMarketDaewoong Ramps NABOTA Training as Toxin Expandsyesterday
Business & M&A

InMode Reports Q2 Revenue $95.2–$95.4M — Steady Growth Amid Acquisition Uncertainty

InMode's preliminary Q2 results show continued revenue momentum despite the pending Steel Partners bid.

Image: Inside MedSpa
1-YEAR MOVE
+3% −14%
INMD ▲1.0%
1-year price move by ticker
TickerCompany1-year change
INMDInMode Ltd.+1.0%

InMode has reported preliminary Q2 2024 revenue of $95.2–$95.4 million, reflecting steady growth in its core RF and body-contouring device business. The company's consumables-driven model—Morpheus8 tips, handpieces, and service contracts—continues to generate recurring revenue despite competitive pressure and the ongoing acquisition process.

The revenue guidance, announced ahead of the formal earnings call, provides a baseline for evaluating Steel Partners' $16.75-per-share bid. At roughly 1.1x revenue (annualized ~$380 million), the offer reflects typical PE multiples for device companies with predictable, high-margin consumables revenue but also signals confidence in InMode's ability to sustain growth.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

InMode's Q2 revenue of $95.2–$95.4 million shows steady growth despite the pending acquisition bid.

For practices, InMode's stability matters: consumable pricing, warranty terms, and software updates depend on ownership structure. A PE takeover could accelerate price increases or bundling strategies, while a competing bid might preserve current terms or trigger strategic alternatives.

Source: original report ↗

Frequently asked questions

What was InMode's Q2 2024 revenue?

InMode reported preliminary Q2 2024 revenue of $95.2–$95.4 million, showing steady growth in its RF and body-contouring device business. This annualizes to approximately $380 million in revenue.

How much is Steel Partners offering to buy InMode for?

Steel Partners' bid values InMode at $16.75 per share, which represents roughly 1.1x annualized revenue—a typical PE multiple for device companies with high-margin consumables revenue.

What happens to Morpheus8 consumable pricing if InMode gets acquired by a PE firm?

A PE takeover could accelerate price increases or bundling strategies for Morpheus8 tips, handpieces, and service contracts. Current consumable pricing, warranty terms, and software updates may change depending on the new ownership structure.

Does InMode's revenue model rely on recurring consumables?

Yes, InMode's consumables-driven model—including Morpheus8 tips, handpieces, and service contracts—generates predictable recurring revenue despite competitive pressure and the ongoing acquisition process.

What should medspa owners know about InMode's acquisition uncertainty?

Practices should monitor the Steel Partners bid outcome, as ownership changes could affect consumable pricing, warranty terms, and software updates. A competing bid or alternative outcome might preserve current terms, while a PE takeover could trigger price increases or new bundling requirements.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://insidemedspa.com/article/inmode-q2-revenue-95-million-preliminary/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa Pro

    By the time it's news, it's too late.

    The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

    Get the free brief Never miss a recall or a rule change. Cancel anytime.
    The twice-a-week intelligence brief Get the free brief